A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

被引:9
作者
Grinshpun, Albert [1 ]
Merlet, Irit [1 ]
Fruchtman, Hila [2 ]
Nachman, Dean [3 ]
机构
[1] Hadassah Hebrew Univ, Sharett Inst Oncol, Med Ctr, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Radiol, Med Ctr, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Internal Med A, Med Ctr, Jerusalem, Israel
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
COVID19; metastatic breast cancer; CDK4; 6; inhibitors; pneumonia; palbociclib; CLINICAL CHARACTERISTICS; PALBOCICLIB; COMBINATION; SAFETY;
D O I
10.3389/fonc.2020.01085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system.
引用
收藏
页数:5
相关论文
共 14 条
  • [1] ECCO, 2020, COVID 19 ECCO TASKF
  • [2] Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18
    Finn, Richard S.
    Crown, John P.
    Ettl, Johannes
    Schmidt, Marcus
    Bondarenko, Igor M.
    Lang, Istvan
    Pinter, Tamas
    Boer, Katalin
    Patel, Ravindranath
    Randolph, Sophia
    Kim, Sindy T.
    Huang, Xin
    Schnell, Patrick
    Nadanaciva, Sashi
    Bartlett, Cynthia Huang
    Slamon, Dennis J.
    [J]. BREAST CANCER RESEARCH, 2016, 18
  • [3] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Bloomquist, Erik
    Sanchez, Jacquelyn
    Wedam, Suparna B.
    Singh, Harpreet
    Amiri-Kordestani, Laleh
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    Prowell, Tatiana M.
    [J]. LANCET ONCOLOGY, 2020, 21 (02) : 250 - 260
  • [4] Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
  • [5] Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
    Guillaume, Zoe
    Medioni, Jacques
    Lillo-Lelouet, Agnes
    Marret, Gregoire
    Oudard, Stephane
    Simonaggio, Audrey
    [J]. CLINICAL BREAST CANCER, 2020, 20 (02) : E192 - E195
  • [6] Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
    Liang, Wenhua
    Guan, Weijie
    Chen, Ruchong
    Wang, Wei
    Li, Jianfu
    Xu, Ke
    Li, Caichen
    Ai, Qing
    Lu, Weixiang
    Liang, Hengrui
    Li, Shiyue
    He, Jianxing
    [J]. LANCET ONCOLOGY, 2020, 21 (03) : 335 - 337
  • [7] Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
    Monti, Sara
    Balduzzi, Silvia
    Delvino, Paolo
    Bellis, Elisa
    Quadrelli, Verdiana Serena
    Montecucco, Carlomaurizio
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (05) : 667 - +
  • [8] FDA approves Novartis's CDK4/6 inhibitor
    Mullard A.
    [J]. Nature Reviews Drug Discovery, 2017, 16 (4) : 229 - 229
  • [9] Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
    Tanguy, Marie-Laure
    Cabel, Luc
    Berger, Frederique
    Pierga, Jean-Yves
    Savignoni, Alexia
    Bidard, Francois-Clement
    [J]. NPJ BREAST CANCER, 2018, 4
  • [10] The trinity of COVID-19: immunity, inflammation and intervention
    Tay, Matthew Zirui
    Poh, Chek Meng
    Renia, Laurent
    MacAry, Paul A.
    Ng, Lisa F. P.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2020, 20 (06) : 363 - 374